Lineage Cell Therapeutics (LCTX) Equity Income (2015 - 2024)

Lineage Cell Therapeutics' Equity Income history runs 10 years deep, the most recent figure standing at -$4000.0 for Q2 2024.

• On a quarterly basis, Equity Income changed N/A year-over-year to -$4000.0 in Q2 2024; TTM through Mar 2025 was -$4000.0, a 82.61% increase from a year earlier, with the FY2024 full-year figure at -$4000.0, up 82.61% from the prior year.
• Equity Income advanced to -$4000.0 in Q2 2024 per LCTX's latest filing, from -$23000.0 in the prior quarter.
• Across five years, Equity Income topped out at $3.7 million in Q4 2020 and bottomed at -$4.1 million in Q2 2020.
• The 5-year median for Equity Income is -$375000.0 (2022), against an average of -$494571.4.
• Across the five-year window, Equity Income surged 114.23% in 2021 and tumbled 220.17% in 2022, its largest moves.
• Year by year, Equity Income stood at $3.7 million in 2020, then slumped by 145.29% to -$1.7 million in 2021, then jumped by 69.19% to -$517000.0 in 2022, then surged by 95.55% to -$23000.0 in 2023, then surged by 82.61% to -$4000.0 in 2024.
• Per Business Quant, the three latest LCTX Equity Income figures stand at -$4000.0 (Q2 2024), -$23000.0 (Q3 2023), and $40000.0 (Q1 2023).